List view / Grid view

Regeneron Pharmaceuticals

Filter the results

 

news

EMA to review Sanofi and Regeneron’s dermatitis drug application

13 December 2016 | By Niamh Louise Marriott, Digital Editor

The European Medicines Agency (EMA) has accepted for review the marketing authorisation application for Sanofi and Regeneron’s Dupixent (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.